First Trust Advisors LP boosted its holdings in shares of Phibro Animal Health Corp (NASDAQ:PAHC) by 20.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,586 shares of the company’s stock after buying an additional 3,769 shares during the period. First Trust Advisors LP’s holdings in Phibro Animal Health were worth $1,040,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Royal Bank of Canada raised its position in Phibro Animal Health by 2,104.6% during the first quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock valued at $151,000 after buying an additional 3,641 shares during the period. Meeder Asset Management Inc. raised its position in Phibro Animal Health by 149.2% during the second quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock valued at $206,000 after buying an additional 2,676 shares during the period. Piedmont Investment Advisors LLC acquired a new position in Phibro Animal Health during the second quarter valued at $213,000. Highbridge Capital Management LLC acquired a new position in Phibro Animal Health during the first quarter valued at $214,000. Finally, Piermont Capital Management Inc. acquired a new position in Phibro Animal Health during the first quarter valued at $223,000. 50.45% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts recently weighed in on the company. BidaskClub raised Phibro Animal Health from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th. Morgan Stanley upped their price target on Phibro Animal Health from $36.00 to $46.00 and gave the company an “underweight” rating in a research report on Wednesday, August 29th. Zacks Investment Research lowered Phibro Animal Health from a “hold” rating to a “sell” rating in a research report on Wednesday, August 29th. Finally, Barclays upped their price target on Phibro Animal Health from $31.00 to $33.00 and gave the company an “underweight” rating in a research report on Thursday, July 5th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $43.20.
In other Phibro Animal Health news, CEO Jack Bendheim sold 10,000 shares of the business’s stock in a transaction dated Monday, August 6th. The stock was sold at an average price of $50.66, for a total value of $506,600.00. Following the transaction, the chief executive officer now owns 8,000 shares in the company, valued at $405,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel M. Bendheim sold 2,500 shares of the business’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $44.30, for a total value of $110,750.00. Following the completion of the transaction, the vice president now owns 2,500 shares in the company, valued at approximately $110,750. The disclosure for this sale can be found here. Insiders sold 383,960 shares of company stock worth $18,474,427 in the last 90 days. Corporate insiders own 51.88% of the company’s stock.
Shares of NASDAQ PAHC opened at $43.35 on Tuesday. The company has a current ratio of 2.90, a quick ratio of 1.66 and a debt-to-equity ratio of 1.62. Phibro Animal Health Corp has a one year low of $32.05 and a one year high of $54.62. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 2.59 and a beta of 0.89.
Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Monday, August 27th. The company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Phibro Animal Health had a return on equity of 39.81% and a net margin of 7.90%. The firm had revenue of $211.80 million for the quarter, compared to the consensus estimate of $209.27 million. During the same quarter in the previous year, the company posted $0.39 earnings per share. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. equities research analysts anticipate that Phibro Animal Health Corp will post 1.8 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 26th. Shareholders of record on Wednesday, September 5th will be paid a $0.10 dividend. The ex-dividend date of this dividend is Tuesday, September 4th. This represents a $0.40 dividend on an annualized basis and a yield of 0.92%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 22.99%.
Phibro Animal Health Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.
Further Reading: Fundamental Analysis – How It Helps Investors
Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corp (NASDAQ:PAHC).
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.